EP3512552A4 - Anti-histone therapy in acute kidney injury - Google Patents
Anti-histone therapy in acute kidney injury Download PDFInfo
- Publication number
- EP3512552A4 EP3512552A4 EP17851497.2A EP17851497A EP3512552A4 EP 3512552 A4 EP3512552 A4 EP 3512552A4 EP 17851497 A EP17851497 A EP 17851497A EP 3512552 A4 EP3512552 A4 EP 3512552A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- histone
- therapy
- kidney injury
- acute kidney
- acute
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394529P | 2016-09-14 | 2016-09-14 | |
| US15/402,585 US20170114126A1 (en) | 2014-06-24 | 2017-01-10 | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
| PCT/US2017/051485 WO2018053080A1 (en) | 2016-09-14 | 2017-09-14 | Anti-histone therapy in acute kidney injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3512552A1 EP3512552A1 (en) | 2019-07-24 |
| EP3512552A4 true EP3512552A4 (en) | 2020-05-06 |
Family
ID=61619282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP17851497.2A Withdrawn EP3512552A4 (en) | 2016-09-14 | 2017-09-14 | Anti-histone therapy in acute kidney injury |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3512552A4 (en) |
| CA (1) | CA3031540A1 (en) |
| WO (1) | WO2018053080A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020172631A2 (en) | 2019-02-21 | 2020-08-27 | Xencor, Inc. | Untargeted and targeted il-10 fc-fusion proteins |
| WO2020225549A1 (en) * | 2019-05-06 | 2020-11-12 | The Francis Crick Institute Limited | Method for preventing inflammation |
| CN113122538A (en) * | 2021-04-15 | 2021-07-16 | 遵义医科大学附属医院 | shRNA expressed by targeted knockdown Rip3 gene, recombinant vector and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9642822B2 (en) * | 2011-05-27 | 2017-05-09 | Children's Medical Center Corporation | Methods for treating and preventing neutrophil-derived net toxicity and thrombosis |
| EP3160504B1 (en) * | 2014-06-24 | 2020-09-16 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
-
2017
- 2017-09-14 EP EP17851497.2A patent/EP3512552A4/en not_active Withdrawn
- 2017-09-14 WO PCT/US2017/051485 patent/WO2018053080A1/en not_active Ceased
- 2017-09-14 CA CA3031540A patent/CA3031540A1/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| "Extracellular histones cause vascular necrosis in severe glomerulonephritis", 2015, UNIVERSITY MÜNCHEN, article VANKAYALA RAMAIAH ET AL: "Extracellular histones cause vascular necrosis in severe glomerulonephritis", XP055678928, DOI: https://edoc.ub.uni-muenchen.de/18767/ * |
| KUMAR SANTHOSH V.R. ET AL: "Neutrophil Extracellular Trap-Related Extracellular Histones Cause Vascular Necrosis in Severe GN", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 26, no. 10, 2 February 2015 (2015-02-02), US, pages 2399 - 2413, XP055926348, ISSN: 1046-6673, DOI: 10.1681/ASN.2014070673 * |
| See also references of WO2018053080A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3512552A1 (en) | 2019-07-24 |
| CA3031540A1 (en) | 2018-03-22 |
| WO2018053080A1 (en) | 2018-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267158B (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| GB201607629D0 (en) | Mutational signatures in cancer | |
| EP3265575A4 (en) | Cd20 binding molecules and uses thereof | |
| EP3575319A4 (en) | Bifunctional molecule and use thereof | |
| SI3423087T1 (en) | Combination therapy against cancer | |
| EP3207162A4 (en) | Combination therapy for use in cancer therapy | |
| ZA201803742B (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| IL263123A (en) | Cancer treatments | |
| GB201511382D0 (en) | Novel compounds and their use in therapy | |
| PT3215158T (en) | Apilimod for use in the treatment of renal cancer | |
| EP3148526A4 (en) | Use of eribulin in the treatment of cancer | |
| EP3367496A4 (en) | Filter unit and filter | |
| EP3266803A4 (en) | Polymer and crosslinked body thereof | |
| EP3102611A4 (en) | Humanized beta-amyloid binding molecules and uses thereof | |
| IL262143A (en) | Improvements in cancer treatment | |
| GB201610948D0 (en) | Improvements in fencing | |
| EP3256473A4 (en) | Synergistic cancer treatment | |
| IL261648A (en) | Cinnolin-4-amine compounds and their use in treating cancer | |
| IL259358A (en) | Bis-pyridazine compounds and their use in treating cancer | |
| EP3160504A4 (en) | Anti-histone therapy for vascular necrosis in severe glomerulonephritis | |
| EP3194957A4 (en) | Method and panel for determining acute kidney injury | |
| HK40008547A (en) | Cobicistat for use in cancer treatments | |
| HK1259160A1 (en) | Bis-pyridazine compounds and their use in treating cancer | |
| AU2016905209A0 (en) | Improvement in Hinges | |
| HK1237824A1 (en) | Combination therapy for use in cancer therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20190409 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20200402 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07C 259/10 20060101ALI20200328BHEP Ipc: C07C 311/21 20060101ALI20200328BHEP Ipc: A61K 39/395 20060101AFI20200328BHEP Ipc: A61P 13/12 20060101ALI20200328BHEP Ipc: C07K 16/18 20060101ALI20200328BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20220603 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20221014 |